Why has MindMaze Therapeutics appointed Zach Henderson as CEO?

MindMaze Therapeutics said Zach Henderson was appointed to help scale its existing commercial presence and accelerate adoption of its FDA-cleared platform in the United States. The company also cited his experience scaling healthcare technology platforms and commercialising AI-driven solutions for complex chronic conditions.

What is Zach Henderson’s background before joining MindMaze Therapeutics?

Zach Henderson has more than 30 years of experience, according to MindMaze Therapeutics. His most recent role was Chief Commercial Officer at Rune Labs, and he previously served as CEO of PKG Health.

What will Zach Henderson focus on as CEO of MindMaze Therapeutics?

MindMaze Therapeutics said Zach Henderson will focus on expanding its U.S. market presence and increasing adoption of its FDA-cleared platform. The company also said his remit includes delivering scalable, AI-driven neurorestorative care.

What did MindMaze Therapeutics’ chairman say about the CEO appointment?

Walid Hanna, Chairman of the Board, said MindMaze Therapeutics had built a rigorous clinical foundation and that its next task was to translate that scientific leadership into wider market adoption. He described Mr Henderson’s operational experience and work across global markets as relevant to the company’s commercial expansion.

How does MindMaze Therapeutics describe its approach to neurological care?

MindMaze Therapeutics said it is shifting care from episodic, clinic-based sessions towards continuous, data-driven neurorestoration in clinical and home settings. The company said this approach is intended to address shortages of neurologists and specialised therapists, including physical and occupational therapists.

What technology and treatments does MindMaze Therapeutics provide?

MindMaze Therapeutics said it combines software, proprietary sensors and AI-driven data analytics to provide care from the acute hospital phase through outpatient treatment and home-based therapy. Its FDA-cleared and CE-marked neurotherapeutics are designed for stroke, Parkinson’s disease and other brain disorders.

Which conditions does MindMaze Therapeutics target?

MindMaze Therapeutics said its neurotherapeutics address stroke, Parkinson’s disease and other brain disorders. The company also referred to patients with Alzheimer’s disease when describing the wider shortage of access to neurological recovery care.

Who has been appointed Chief Operating and Strategy Officer at MindMaze Therapeutics?

Alexandre Capet has been appointed Chief Operating and Strategy Officer at MindMaze Therapeutics. The company said he will continue as a standing member of its Executive Committee.

Where are MindMaze Therapeutics shares listed and what is the ticker symbol?

MindMaze Therapeutics is identified in the announcement as listed on SIX under the ticker symbol MMTX.

Home
News Intelligence
MindMaze Therapeutics Holding SA
MindMaze Therapeutics Names Zach Henderson CEO as Company Targets U.S. Expansion

Back to all MindMaze Therapeutics Holding SA press releases

MindMaze Therapeutics Holding SA

OTCQB:MMTZF
SIX:MMTX

MindMaze Therapeutics Names Zach Henderson CEO as Company Targets U.S. Expansion

Published Thursday, 12 March 2026, 06:00 AM

Get alerts

Plain English summaries when MindMaze Therapeutics Holding SA announces news.

At a glance

Company: MindMaze Therapeutics Holding SA
Listings: OTCQB:MMTZF, SIX:MMTX
Announcement type: Management change
Published: Thursday, 12 March 2026, 06:00 AM
Source announcement: eqs-news.com

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

MindMaze Therapeutics Holding SA (SIX: MMTX) announced on March 12, 2026, that it appointed Zach Henderson as Chief Executive Officer. The company said he will focus on U.S. market expansion and adoption of its FDA-cleared platform.

Henderson has over 30 years of experience. His most recent role was Chief Commercial Officer at Rune Labs, and he previously served as CEO of PKG Health. The company also appointed Alexandre Capet as Chief Operating and Strategy Officer; he will continue as a standing member of the Executive Committee.

Investor FAQs

MindMaze Therapeutics announced the appointment of Zach Henderson as Chief Executive Officer on March 12, 2026. The company said he will lead its next phase of growth, with a focus on U.S. market expansion and scalable, AI-driven neurorestorative care.

Source announcement

Company: MindMaze Therapeutics Holding SA
Title: MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale
Published: Thursday, 12 March 2026, 06:00 AM
Source site: eqs-news.com

Read the source announcement on eqs-news.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…